Relmada Therapeutics (STU:4E2) Interest Expense : €0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Relmada Therapeutics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Relmada Therapeutics's interest expense for the three months ended in Dec. 2024 was € 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2024 was €0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Relmada Therapeutics's Operating Income for the three months ended in Dec. 2024 was € -18.22 Mil. Relmada Therapeutics's Interest Expense for the three months ended in Dec. 2024 was € 0.00 Mil. Relmada Therapeutics has no long-term debt ⁽¹⁾. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Relmada Therapeutics Interest Expense Historical Data

The historical data trend for Relmada Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Relmada Therapeutics Interest Expense Chart

Relmada Therapeutics Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Dec20

Dec21

Dec22

Dec23

Dec24

Interest Expense

Get a 7-Day Free Trial

Relmada Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-

Relmada Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

Relmada Therapeutics (STU:4E2) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Relmada Therapeutics's Interest Expense for the three months ended in Dec. 2024 was €0.00 Mil. Its Operating Income for the three months ended in Dec. 2024 was €-18.22 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2024 was €0.00 Mil.

Relmada Therapeutics's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as

Relmada Therapeutics had no long-term debt ⁽¹⁾.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Relmada Therapeutics Inc has no debt.

Relmada Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relmada Therapeutics Inc (STU:4E2) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

RLMD:USA

Address

2222 Ponce de Leon Boulevard, Floor 3, Coral Gables, FL, USA, 33134

Website

https://www.relmada.com

Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.

Relmada Therapeutics Headlines

No Headlines